These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30277471)

  • 1. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
    Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
    J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
    Lewinsky H; Gunes EG; David K; Radomir L; Kramer MP; Pellegrino B; Perpinial M; Chen J; He TF; Mansour AG; Teng KY; Bhattacharya S; Caserta E; Troadec E; Lee P; Feng M; Keats J; Krishnan A; Rosenzweig M; Yu J; Caligiuri MA; Cohen Y; Shevetz O; Becker-Herman S; Pichiorri F; Rosen S; Shachar I
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33465053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
    McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
    Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD84 mediates CLL-microenvironment interactions.
    Marom A; Barak AF; Kramer MP; Lewinsky H; Binsky-Ehrenreich I; Cohen S; Tsitsou-Kampeli A; Kalchenko V; Kuznetsov Y; Mirkin V; Dezorella N; Shapiro M; Schwartzberg PL; Cohen Y; Shvidel L; Haran M; Becker-Herman S; Herishanu Y; Shachar I
    Oncogene; 2017 Feb; 36(5):628-638. PubMed ID: 27452524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
    McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
    Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
    Gassner FJ; Zaborsky N; Catakovic K; Rebhandl S; Huemer M; Egle A; Hartmann TN; Greil R; Geisberger R
    Br J Haematol; 2015 Aug; 170(4):515-22. PubMed ID: 25940792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD84 is a Suppressor of T and B Cell Activation during Mycobacterium tuberculosis Pathogenesis.
    Zheng N; Fleming J; Hu P; Jiao J; Zhang G; Yang R; Li C; Liu Y; Bi L; Zhang H
    Microbiol Spectr; 2022 Feb; 10(1):e0155721. PubMed ID: 35196822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
    Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
    Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
    Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia.
    Grzywnowicz M; Karczmarczyk A; Skorka K; Zajac M; Zaleska J; Chocholska S; Tomczak W; Giannopoulos K
    Acta Haematol; 2015; 134(4):255-62. PubMed ID: 26159545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD84 is a survival receptor for CLL cells.
    Binsky-Ehrenreich I; Marom A; Sobotta MC; Shvidel L; Berrebi A; Hazan-Halevy I; Kay S; Aloshin A; Sagi I; Goldenberg DM; Leng L; Bucala R; Herishanu Y; Haran M; Shachar I
    Oncogene; 2014 Feb; 33(8):1006-16. PubMed ID: 23435417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
    Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
    Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does PD-L1 positive or negative mean?
    Ribas A; Hu-Lieskovan S
    J Exp Med; 2016 Dec; 213(13):2835-2840. PubMed ID: 27903604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
    Grzywnowicz M; Zaleska J; Mertens D; Tomczak W; Wlasiuk P; Kosior K; Piechnik A; Bojarska-Junak A; Dmoszynska A; Giannopoulos K
    PLoS One; 2012; 7(4):e35178. PubMed ID: 22532845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner.
    Barak AF; Lewinsky H; Perpinial M; Huber V; Radomir L; Kramer MP; Sever L; Wolf Y; Shapiro M; Herishanu Y; Jung S; Becker-Herman S; Shachar I
    Oncogene; 2020 Feb; 39(9):1997-2008. PubMed ID: 31772329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
    Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
    Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
    Hanna BS; McClanahan F; Yazdanparast H; Zaborsky N; Kalter V; Rößner PM; Benner A; Dürr C; Egle A; Gribben JG; Lichter P; Seiffert M
    Leukemia; 2016 Mar; 30(3):570-9. PubMed ID: 26522085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
    Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
    J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.